GSK plc (NYSE:GSK) ranks among the best undervalued European stocks to buy now. On February 4, GSK plc (NYSE:GSK) announced fourth-quarter earnings that outperformed analyst estimates in several important metrics. Earnings per share for the quarter came in at $0.6989, 9.58% more than the forecast of $0.6378. Revenue also surpassed forecasts, coming in at $11.81 billion versus $11.36 billion, for a 3.96% upside surprise.
Pixabay/Public Domain
Specialty Medicines was a fairly promising area, with 17% growth, while Oncology outperformed expectations, with sales up 43% from the same quarter last year.
GSK plc (NYSE:GSK) issued upbeat guidance for 2026, projecting 3-5% sales growth. The company forecasts core operating profit and earnings per share to rise even faster, at 7-9%, implying further margin expansion. The company’s management stated that oncology and respiratory medicines, as well as expanding pipeline assets, will be the main drivers of future growth.
GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company that researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders.
While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. This article is originally published at Insider Monkey.
